Skip to main content

Month: April 2021

EfTEN Real Estate Fund III AS unaudited results for 1st quarter 2021

Despite of accelerated spread of Covid-19 and increased restrictions, the fund’s results for the first quarter of 2021 are beyond expectations good. The rental income of Saules Miestas shopping centre in Lithuania has decreased by 22% on average compared to the first quarter of previous year, due to temporary discounts, but the rental income of other properties was not materially affected by the crisis. At the same time, there are additional agreements in place with some of the tenants to postpone rental payments until May, which may have negative impact to fund’s cash flows. The consolidated revenue of EfTEN Real Estate fund III AS for the first quarter of 2021 was 2.867 million euros (2020 I quarter: 2.443 million euros), increased by 17.4% compared to previous year. The Group’s net rental income in the first quarter of 2021 was 2.770...

Continue reading

Angion and Vifor Pharma Announce Completion of Enrollment in Phase 2 Study of ANG-3777 for Cardiac-Surgery Associated Acute Kidney Injury

Topline data expected in the second half of 2021 UNIONDALE, N.Y. and ST. GALLEN, Switzerland, April 29, 2021 (GLOBE NEWSWIRE) — Angion Biomedica Corp (NASDAQ:ANGN) and Vifor Pharma today announced completion of enrollment for Angion’s AKI-002-15 study, a Phase 2 trial of ANG-3777 in patients at risk of cardiac-surgery associated acute kidney injury (CSA-AKI). This indication is part of the ANG-3777 license agreement both parties signed in November 2020. “CSA-AKI is a frequent complication of cardiac bypass surgery seen in about one third of patients and is associated with prolonged hospitalization, progressive kidney failure, and an increased risk of death,” commented Dr. John Neylan, Angion’s Senior Vice President and Chief Medical Officer. “Currently, there are no approved therapies to prevent this serious condition. This Phase...

Continue reading

DMG Blockchain Solutions Announces CDN$28.1 Million Private Placement Offering with Institutional Investors

NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia, April 28, 2021 (GLOBE NEWSWIRE) — DMG Blockchain Solutions Inc. (TSXV: DMGI) (DMGGF: OTCQB) (FSE: 6AX) (“DMG” or the “Company”), a vertically integrated blockchain and cryptocurrency technology company is pleased to announce that it has entered into a securities purchase agreement for a private placement of its common shares (“Common Shares”) and warrants to purchase common shares (“Warrants”) to institutional investors only for aggregate gross proceeds to the Company of approximately Cdn$28.1 million (the “Private Placement”). Pursuant to the Private Placement, the Company will issue 22,297,644 Common Shares and Warrants to purchase up to 22,297,644...

Continue reading

Retransmission: Red White & Bloom Closes Acquisition of Florida Operations from Acreage Holdings

TORONTO, April 28, 2021 (GLOBE NEWSWIRE) — Red White & Bloom Brands Inc. (CSE: RWB and OTC: RWBYF) (“RWB” or the “Company”) is pleased to announce that, further to its press release of February 25, 2021, its new subsidiary, RWB Florida LLC, has completed the acquisition of all of the issued and outstanding shares of Acreage Florida, Inc. (“Acreage Florida”) from High Street Capital Partners, LLC (the “Seller”), a subsidiary of Acreage Holdings Inc. (“Acreage”) (CSE: ACRG.A.U; ACRG.B.U) (OTCQX: ACRDF, ACRHF). RWB also completed the acquisition of certain owned and leased real estate assets used in Acreage Florida’s operations (the “Florida Real Estate”).  RWB Florida is licensed to operate medical marijuana dispensaries, a processing facility, and a cultivation facility in the state of Florida. The Company wishes to correct...

Continue reading

Burning Rock Schedules First Quarter of 2021 Earnings Release on May 25, 2021

GUANGZHOU, China, April 28, 2021 (GLOBE NEWSWIRE) — Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today announced that it plans to release its unaudited financial results for the first quarter of 2021 before the U.S. market opens on May 25, 2021. Following the release, company management will host a conference call at 8:00 a.m. ET (8:00 p.m. Hong Kong time) on the same day to discuss its financial results for the first quarter of 2021. Details of the conference call are as follows:International: +65 67135090U.S.: +1 8456750437U.K.: +44 2036214779Hong Kong: +852 30186771China Mobile: 4006208038China Landline: 8008190121Conference ID: 6193891A replay of...

Continue reading

Fanhua Files 2020 Annual Report on Form 20-F with the SEC

GUANGZHOU, China, April 28, 2021 (GLOBE NEWSWIRE) — Fanhua Inc. (“Fanhua” or “the Company”) (Nasdaq: FANH), a leading independent financial services provider in China, today announced that it has filed its 2020 annual report on Form 20-F, which contains its audited financial statements for the fiscal year ended December 31, 2020, with the U.S. Securities and Exchange Commission (the “SEC”) on April 28, 2021. The 2020 20-F can be accessed on the SEC’s website at http://www.sec.gov as well as on the Investor Relations page of the Company’s website at http://ir.fanhuaholdings.com/financial-information/sec-filings. Hard copies of the annual report are available, free of charge, to its shareholders upon request. About Fanhua Inc. Fanhua Inc. is a leading independent financial services provider. Through our online platforms and...

Continue reading

Hydrofarm Holdings Group Announces Pricing of Upsized Public Offering of Common Stock

FAIRLESS HILLS, Pa., April 28, 2021 (GLOBE NEWSWIRE) — Hydrofarm Holdings Group, Inc. (“Hydrofarm” or the “Company”) (Nasdaq: HYFM), a leading independent distributor and manufacturer of hydroponics equipment and supplies for controlled environment agriculture, today announced the pricing of an underwritten upsized public offering of 4,805,967 shares of its common stock at a public offering price of $59.00 per share. The net proceeds to the Company from this offering, after deducting the underwriting discounts and commissions and estimated offering expenses payable by the Company, are expected to be approximately $269.3 million. All shares of common stock are being offered by Hydrofarm. In addition, the Company has granted the underwriters a 30-day option to purchase up to an additional 720,894 of its common stock at the public...

Continue reading

Major Precious Metals Unaware of Any Material Change

VANCOUVER, British Columbia, April 28, 2021 (GLOBE NEWSWIRE) — Major Precious Metals Corp. (“Major Precious Metals” or the “Company”) (CSE:SIZE | OTC:SIZYF | FRANKFURT:3EZ) wishes to confirm that management is unaware of any material change in the Company’s operations that would account for the recent significant share price depreciation, following the successful report of its 5.5 million palladium equivalent indicated resource and 14.4 million palladium equivalent ounce inferred resource at Skaergaard. The Company has been informed by its advisors that sophisticated techniques including spoofing, layering, wash trading, manipulation through multiple brokerage houses and the use of aggressive algorithms targeting the bid/offer designed to give the appearance of weakness in the Company’s shares have been utilized in...

Continue reading

Magnetic North Acquisition Corp. Announces Delay in Filing of Annual Financial Statements and Application for Management Cease Trade Order

CALGARY, Alberta and TORONTO, April 28, 2021 (GLOBE NEWSWIRE) — Magnetic North Acquisition Corp. (TSXV: MNC; MNC.PR.A) (“Magnetic North” or the “Company”) announces that it will not meet the filing date for filing of the following continuous disclosure documents (collectively, the “Documents”):the Company’s Annual Audited Financial Statements for the 15 months ended December 31, 2020, as required by section 4.2 of National Instrument 51-102 – Continuous Disclosure Obligations (“NI 51-102”); and the Company’s Management Discussion & Analysis for the 15 months ended December 31, 2020, as required by section 5.1(2) of NI 51-102.The default is due, in part, to business and administrative disruption experienced by the Company in respect of both its own personnel and the Company’s auditors inability to complete the work...

Continue reading

GW Pharmaceuticals recognised for leadership in prescription cannabis-based medicines with prestigious Queen’s Award for Enterprise in Innovation

GW’s ground-breaking medicines development programme recognised for outstanding achievement in innovation with UK’s highest official award for British business LONDON, April 29, 2021 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (Nasdaq: GWPH) (“GW”, “the Company” or “the Group”), a world leader in discovering, developing and commercialising regulatory approved cannabis-based medicines, announces that it has received the Queen’s Award for Enterprise 2021 in the Innovation category, recognising GW’s innovative and ground-breaking work to harness cannabinoid science to create the world’s first regulatory approved, prescription cannabis-based medicines. Since its inception in 1998, GW has successfully navigated significant barriers to enable the development, manufacture and commercialisation of regulatory approved cannabis-based medicines,...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.